Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Molecules (Basel, Switzerland)|February 9, 2008
Antiparkinson prodrugsAntonio Di Stefano, Piera Sozio, Laura Serafina CerasaExpert Opinion on Drug Delivery|March 12, 2011
Drug delivery strategies for Alzheimer's disease treatmentAntonio Di Stefano, Antonio Iannitelli, Sara Laserra, et al.Expert Opinion on Drug Delivery|April 23, 2009
New drug delivery strategies for improved Parkinson's disease therapyAntonio Di Stefano, Piera Sozio, Antonio Iannitelli, et al.Expert Opinion on Drug Discovery|April 13, 2012
Designing prodrugs for the treatment of Parkinson's diseasePiera Sozio, Laura Serafina Cerasa, Anna Abbadessa, et al.Current Pharmaceutical Design|November 15, 2011
L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatmentAntonio Di Stefano, Piera Sozio, Laura Serafina Cerasa, et al.Neuropsychiatric Disease and Treatment|September 4, 2012
Transdermal donepezil on the treatment of Alzheimer's diseasePiera Sozio, Laura S Cerasa, Lisa Marinelli, et al.Cytotechnology|February 5, 2014
Protective effects of cyclosativene on H2O 2-induced injury in cultured rat primary cerebral cortex cellsHasan Turkez, Basak Togar, Antonio Di Stefano, et al.Journal of Peptide Science : an Official Publication of the European Peptide Society|March 5, 2004
Transition state isosteres of the gamma-glutamyl peptide bond hydrolysis: synthesis and characterization of the psi (CH2NH) pseudopeptide analogue of glutathioneIvana Cacciatore, Antonio Di Stefano, Grazia Luisi, et al.Cellular and Molecular Neurobiology|October 10, 2013
Neuroprotective effects of farnesene against hydrogen peroxide-induced neurotoxicity in vitroHasan Turkez, Piera Sozio, Fatime Geyikoglu, et al.Journal of Drug Targeting|November 9, 2006
Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulationAntonio Di Stefano, Piera Sozio, Antonio Iannitelli, et al.Pageof 4